Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus DOXYCHEL HYCLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus DOXYCHEL HYCLATE.
DECLOMYCIN vs DOXYCHEL HYCLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA binding to the mRNA-ribosome complex.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
100 mg orally or IV every 12 hours on day 1, then 100 mg daily.
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Terminal elimination half-life is 18–22 hours in patients with normal renal function; prolonged to 20–30 hours in severe renal impairment. Clinical context: Allows once- or twice-daily dosing.
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Doxycycline hyclate is primarily excreted via the feces (approximately 90%) as an inactive chelated complex, with renal excretion accounting for about 10% of the dose. Biliary excretion is minimal.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic